TickerTalks
Browse all tickers →
TickerTalks›$INCR
ININCR

InterCure Ltd.

$INCR·$65M·Drug Manufacturers - Specialty & Generic·Healthcare
$5.90+2.1%1Y-28.6%
Mentions · last 7 days
2026-08-21: 6 posts2026-08-22: 11 posts2026-08-23: 8 posts2026-08-24: 36 posts67
Price updated 9m ago·X counts updated 7d ago
ININCR
$INCRInterCure Ltd.
$5.90+2.08%67 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $INCR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-08-26

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

InterCure landed a NIS 230M ($77M) war-damages settlement plus US federal cannabis-rescheduling review — coiled Israeli cannabis play.

InterCure Ltd. is an Israeli medical-cannabis operator (Canndoc brand) with pharma-manufacturing standards and diversified international operations. Recent settlement plus US medical-cannabis strategic review put concrete catalysts on the setup.

  • The war-damages settlement is a material one-off cash unlock: NIS 230 million (~$77M) settlement for war-related indirect damages — that's roughly 118% of the current $65M market cap, a genuine balance-sheet-repair event that changes the risk/reward materially.
  • The strategic-review catalyst is timely: InterCure initiated strategic review of US medical-cannabis opportunities following historic federal rescheduling — and completed the initial closing of the Botanico acquisition; the US-cannabis-rescheduling backdrop is a real category tailwind that positions INCR uniquely as a Israel-listed operator with pharma-grade standards.
  • The tape is coiled and moving: at 49% of the 52-week range, 21% above the 50-day and 21% above the 200-day on 2.85x elevated volume with beta 0.57 — today's +7.3% pop plus the elevated volume signals genuine buying interest around the settlement + strategic review headlines; small NIS 22M private-placement financing was priced.

The path if this works is a signed US market-entry transaction plus continued Botanico-integration progress, taking the tape past $8. What breaks it is a strategic-review process stalling or a fresh dilutive raise — the settlement cash provides cushion but the equity thesis is now about US-cannabis-rescheduling execution.

Agrees with X sentimentNo detailed X sentiment sample was surfaced beyond news headlines — the NIS 230M settlement, NIS 22M pharma-focused hedge-fund private placement, US medical cannabis strategic review, and Botanico acquisition initial closing are the concrete catalysts supporting the coiled turnaround.

What to watch: Next quarterly print (schedule TBD) — settlement-cash deployment plus concrete US-market-entry transaction extends the tape past $8; a strategic-review process stalling or a fresh dilutive raise breaks the coil back to $4. Any US-cannabis-rescheduling regulatory milestone is the leading category catalyst.

Read the AI verdict + X sentiment for $INCR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

InterCure is Israel's largest cannabis company, operating cultivation, processing, and pharmacy distribution networks.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $INCR.

Drug Manufacturers - Specialty & Generic · Healthcare

Biosimilar launches are compressing margins on branded specialty drugs; the opportunity is on the generic/biosimilar side where volume gains offset price erosion. Rare disease and oncology are the premium pockets where pricing power remains intact.

What this means for $INCR

Neutral — InterCure Ltd; exposure to the industry macro driver is limited or indirect.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+47.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-4.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-10.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
7.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-8.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
15.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2025Sep 1, 2025$-0.02——
Q1 2025May 1, 2025$-0.02——
Q3 2024Dec 13, 2024$-1.04——
Q2 2024Aug 30, 2024$0.02——

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$70.1M+23.9%0.3%-23.5%$-1.70$13.3M
Q3 FY25$70.1M+23.9%0.3%-23.5%$-1.70$2.2M
Q2 FY25$65.0M+3.4%30.9%4.4%$-0.07$4.5M
Q1 FY25$65.0M+3.4%30.9%4.4%$-0.07$4.5M

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.47%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+17.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+18.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 7.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.575-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 1 other (1 award) in window

See when $INCR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsApr 203
3New insider — initial holdingsApr 203
3New insider — initial holdingsApr 203
3New insider — initial holdingsApr 163
3New insider — initial holdingsApr 163
3New insider — initial holdingsApr 163
+ 11 other (8 6-Ks · 1 D · 1 6-K/A · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damagesglobenewswire.com·8d agoInterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Fundsglobenewswire.com·70d agoInterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisitionglobenewswire.com·77d agoInterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisitionglobenewswire.com·77d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$EVO$ACB$TEVA$ETON$BHC$ELAN$CRON$ZYBT
Voices on X · last 7 days

No standout posts about $INCR on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport